Lymphocyte subset analyses and outcomes
Group, Patient no. . | LC30, × 109/L . | CD8 CD3+CD8+, % (× 109/L) . | CD4 CD3+CD4+, % (× 109/L) . | NK30, % (× 109/L) . | MR at 3 mo . | Outcome . |
|---|---|---|---|---|---|---|
| Group A | ||||||
| 12 | 0.032 | 18.3 (0.006) | 17.7 (0.006) | 56.7 (0.018) | Yes | Died; GVHD |
| 17 | 0.052 | 17.8 (0.009) | 5.1 (0.003) | 65.7 (0.034) | No | Died; relapse |
| 27 | 0.171 | 23.3 (0.040) | 17.9 (0.031) | 33.9 (0.058) | No | Alive; in MR |
| 36 | 0.030 | 1.54 (0.001) | 2.23 (0.007) | 86.3 (0.026) | NA | Died; viral encephalitis |
| 73 | 0.102 | 20.6 (0.021) | 19.4 (0.020) | 60.2 (0.061) | No | Died; relapse |
| 258 | 0.117 | 13.1 (0.015) | 3 (0.004) | 61.9 (0.072) | No | Died; IP |
| 283 | 0.278 | 48.7 (0.135) | 10.9 (0.030) | 22.7 (0.063) | No | Alive; MRel |
| 285 | 0.172 | 31.5 (0.054) | 17.4 (0.030) | 36.5 (0.063) | NA | Died; IP |
| 286 | 0.199 | 70.3 (0.140) | 6.8 (0.014) | 15.1 (0.030) | No | Alive; APRel* |
| 400 | 0.182 | 51.4 (0.094) | 23 (0.042) | 17.3 (0.031) | NA | Died; relapse |
| Group B | ||||||
| 1 | 0.622 | 3.6 (0.022) | 28.3 (0.176) | 44.4 (0.276) | Yes | Alive; in MR |
| 28 | 0.632 | 31.4 (0.198) | 3.5 (0.022) | 52 (0.328) | Yes | Alive; in MR |
| 31 | 0.918 | 16.6 (0.152) | 5 (0.046) | 60.8 (0.558) | Yes | Alive; in MR |
| 237 | 0.817 | 0 (0) | 9.1 (0.074) | 18.2 (0.149) | Yes | Alive; in MR |
| 262 | 0.449 | 18.6 (0.084) | 20.2 (0.091) | 43.7 (0.196) | Yes | Alive; in MR |
| 264 | 0.534 | 27.5 (0.147) | 11.4 (0.061) | 27.9 (0.149) | Yes | Alive; in MR |
| 270 | 1.498 | 13.2 (0.198) | 5.1 (0.076) | 67.1 (1.005) | Yes | Alive; in MR |
| 273 | 0.656 | 40.7 (0.267) | 8.8 (0.058) | 35.1 (0.230) | Yes | Alive; in MR |
| 335 | 0.874 | 39.9 (0.349) | 13.3 (0.116) | 37.7 (0.330) | Yes | Alive; in MR |
| 393 | 0.641 | 19 (0.122) | 7.5 (0.048) | 60.8 (0.390) | Yes | Alive; in MR |
Group, Patient no. . | LC30, × 109/L . | CD8 CD3+CD8+, % (× 109/L) . | CD4 CD3+CD4+, % (× 109/L) . | NK30, % (× 109/L) . | MR at 3 mo . | Outcome . |
|---|---|---|---|---|---|---|
| Group A | ||||||
| 12 | 0.032 | 18.3 (0.006) | 17.7 (0.006) | 56.7 (0.018) | Yes | Died; GVHD |
| 17 | 0.052 | 17.8 (0.009) | 5.1 (0.003) | 65.7 (0.034) | No | Died; relapse |
| 27 | 0.171 | 23.3 (0.040) | 17.9 (0.031) | 33.9 (0.058) | No | Alive; in MR |
| 36 | 0.030 | 1.54 (0.001) | 2.23 (0.007) | 86.3 (0.026) | NA | Died; viral encephalitis |
| 73 | 0.102 | 20.6 (0.021) | 19.4 (0.020) | 60.2 (0.061) | No | Died; relapse |
| 258 | 0.117 | 13.1 (0.015) | 3 (0.004) | 61.9 (0.072) | No | Died; IP |
| 283 | 0.278 | 48.7 (0.135) | 10.9 (0.030) | 22.7 (0.063) | No | Alive; MRel |
| 285 | 0.172 | 31.5 (0.054) | 17.4 (0.030) | 36.5 (0.063) | NA | Died; IP |
| 286 | 0.199 | 70.3 (0.140) | 6.8 (0.014) | 15.1 (0.030) | No | Alive; APRel* |
| 400 | 0.182 | 51.4 (0.094) | 23 (0.042) | 17.3 (0.031) | NA | Died; relapse |
| Group B | ||||||
| 1 | 0.622 | 3.6 (0.022) | 28.3 (0.176) | 44.4 (0.276) | Yes | Alive; in MR |
| 28 | 0.632 | 31.4 (0.198) | 3.5 (0.022) | 52 (0.328) | Yes | Alive; in MR |
| 31 | 0.918 | 16.6 (0.152) | 5 (0.046) | 60.8 (0.558) | Yes | Alive; in MR |
| 237 | 0.817 | 0 (0) | 9.1 (0.074) | 18.2 (0.149) | Yes | Alive; in MR |
| 262 | 0.449 | 18.6 (0.084) | 20.2 (0.091) | 43.7 (0.196) | Yes | Alive; in MR |
| 264 | 0.534 | 27.5 (0.147) | 11.4 (0.061) | 27.9 (0.149) | Yes | Alive; in MR |
| 270 | 1.498 | 13.2 (0.198) | 5.1 (0.076) | 67.1 (1.005) | Yes | Alive; in MR |
| 273 | 0.656 | 40.7 (0.267) | 8.8 (0.058) | 35.1 (0.230) | Yes | Alive; in MR |
| 335 | 0.874 | 39.9 (0.349) | 13.3 (0.116) | 37.7 (0.330) | Yes | Alive; in MR |
| 393 | 0.641 | 19 (0.122) | 7.5 (0.048) | 60.8 (0.390) | Yes | Alive; in MR |
Patients in group A: LC30 count less than 0.3 × 109/L; group B: greater than or equal to 0.3 × 109/L.
MR indicates molecular remission; IP, interstitial pneumonitis; MRel, molecular relapse; APRel, advanced-phase relapse; NA, not applicable.
Patient experienced relapse after second transplantation but achieved MR after salvage therapy with combination DLI and imatinib